The Food and Drug Administration (FDA) has approved Merus NV’s therapy Bizengri, the first treatment targeting the NRG1 gene, offering new hope for patients with challenging forms of lung and pancreatic cancers. The FDA announced the approval on Wednesday, marking a significant milestone in cancer treatment.
Bizengri is specifically designed to treat tumors associated with the NRG1 gene fusion, which plays a key role in the formation and progression of certain cancers. This breakthrough therapy provides a targeted option for patients suffering from non-small-cell lung cancer (NSCLC) and pancreatic adenocarcinoma with the NRG1 fusion, conditions for which treatment options are often limited.
The approval represents a step forward in precision medicine, tailoring treatments to the genetic makeup of specific tumors, and expanding options for patients with these hard-to-treat cancers.
